CompanyHealth
ReCode Therapeutics
ReCode Therapeutics is a clinical-stage genetic medicines company using its Selective Organ Targeting (SORT) lipid nanoparticle platform to deliver mRNA and gene-correction therapies beyond the liver. Its lead programs target cystic fibrosis and primary ciliary dyskinesia - rare respiratory diseases where existing modulators leave many patients without options.
2015Founded
Menlo ParkHQ
$29M+Additional financing
biotechgenetic medicineslipid nanoparticleslnpmrnacystic fibrosis